Durvalumab + olaparib 45% Reduction Disease Progression in Endometrial - ESMO 2023

Dive into the world of Durvalumab, a cutting-edge immunotherapy revolutionizing cancer treatment. Discover its potential, benefits, and the latest research findings. Explore how Durvalumab is changing the landscape of oncology.


By. Shannon Westin, MD
Date. October 27, 2023

In the video interview, Shannon Westin, MD, discusses the key findings from the DUO-E Phase III trial, focusing on the combination of IMFINZI® (durvalumab) and LYNPARZA® (olaparib) in advanced or recurrent endometrial cancer and its implications for patient treatment options.

Dr. Shannon Westin highlights the significant impact of the DUO-E Phase III trial findings on the management of advanced or recurrent endometrial cancer. She emphasizes that the combination of IMFINZI® and LYNPARZA® showed a remarkable 45% reduction in the risk of disease progression or death when compared to chemotherapy in the overall trial population. This reduction signifies a substantial advancement in the treatment of endometrial cancer, offering patients a promising alternative to traditional chemotherapy.

Furthermore, Dr. Westin elaborates on an exploratory analysis based on Mismatch Repair (MMR) status. She explains that MMR status does influence the efficacy of the IMFINZI® plus LYNPARZA® combination. Certain patient groups, particularly those with specific MMR status, demonstrated a more pronounced benefit from this combination therapy. This highlights the potential for personalized treatment approaches based on MMR status to optimize patient outcomes.

In the case of patients who are PD-L1 positive, Dr. Westin points out that the reduction in the risk of disease progression or death was substantial. These results suggest that PD-L1 status can serve as a valuable biomarker for guiding treatment decisions in endometrial cancer. This approach could help identify patients who are most likely to benefit from the IMFINZI® and LYNPARZA® combination, leading to more tailored and effective treatment plans.

Dr. Westin further discusses the safety and tolerability profiles of the treatments. She explains the most common adverse events reported in patients treated with IMFINZI® plus LYNPARZA® and IMFINZI® alone. While some side effects may occur, she emphasizes that these are generally manageable, and the benefits of the treatment combination outweigh the associated risks, especially considering the improvement in disease progression or death risk.

As for the next steps for this data, Dr. Westin anticipates that it will lead to further research and clinical trials, with the aim of refining treatment strategies and potentially expanding the application of IMFINZI® and LYNPARZA® in the management of endometrial cancer. This data will likely play a crucial role in shaping the future of endometrial cancer treatment and advancing patient care in this field.